In-Depth Site-Specific O-Glycosylation Analysis of Glycoproteins and Endogenous Peptides in Cerebrospinal Fluid (CSF) from Healthy Individuals, Mild Cognitive Impairment (MCI), and Alzheimer’s Disease (AD) Patients
Authors:
- 29 December 2021
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Chemical Biology
- Vol. 17 (11) , 3059-3068
Abstract
Site-specific O-glycoproteome mapping in complex biological systems provides a molecular basis for understanding the structure–function relationships of glycoproteins and their roles in physiological and pathological processes. Previous O-glycoproteome analysis in cerebrospinal fluid (CSF) focused on sialylated glycoforms, while missing information on other glycosylation types. In order to achieve an unbiased O-glycosylation profile, we developed an integrated strategy combining universal boronic acid enrichment, high-pH fractionation, and electron-transfer and higher-energy collision dissociation (EThcD) for enhanced intact O-glycopeptide analysis. We applied this strategy to analyze the O-glycoproteome in CSF, resulting in the identification of 308 O-glycopeptides from 110 O-glycoproteins, covering both sialylated and nonsialylated glycoforms. To our knowledge, this is the largest data set of O-glycoproteins and O-glycosites reported for CSF to date. We also developed a peptidomics workflow that utilized the EThcD and a three-step database searching strategy for comprehensive PTM analysis of endogenous peptides, including N-glycosylation, O-glycosylation, and other common peptide PTMs. Interestingly, among the 1411 endogenous peptides identified, 89 were O-glycosylated, and only one N-glycosylated peptide was found, indicating that CSF endogenous peptides were predominantly O-glycosylated. Analyses of the O-glycoproteome and endogenous peptidome PTMs were also conducted in the CSF of MCI and AD patients to provide a landscape of glycosylation patterns in different disease states. Our results showed a decreasing trend in fucosylation and an increasing trend of endogenous peptide O-glycosylation, which may play an important role in AD progression.Keywords
Funding Information
- National Cancer Institute (U01CA231081)
- Wisconsin Alumni Research Foundation
- National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK071801)
- National Institute on Aging (P30AG062715, R21AG065728, RF1 AG052324)
- University of Wisconsin-Madison
This publication has 65 references indexed in Scilit:
- Mucin-type O-Glycosylation during DevelopmentJournal of Biological Chemistry, 2013
- Investigation and reduction of sub‐microgram peptide loss using molecular weight cut‐off fractionation prior to mass spectrometric analysisJournal of Mass Spectrometry, 2012
- Peptidome Analysis of Cerebrospinal Fluid by LC-MALDI MSPLOS ONE, 2012
- Neuropeptides and Other Bioactive Peptides: From Discovery to FunctionColloquium Series on Neuropeptides, 2012
- Site-specific characterization of threonine, serine, and tyrosine glycosylations of amyloid precursor protein/amyloid β-peptides in human cerebrospinal fluidProceedings of the National Academy of Sciences, 2011
- Proteomics of human cerebrospinal fluid – the good, the bad, and the uglyProteomics – Clinical Applications, 2007
- Extended Core 1 and Core 2 Branched O-Glycans Differentially Modulate Sialyl Lewis x-type L-selectin Ligand ActivityJournal of Biological Chemistry, 2003
- Human Choroid Plexus Growth Factors: What Are the Implications for CSF Dynamics in Alzheimer's Disease?Experimental Neurology, 2001
- In Defense of the Oral Cavity: Structure, Biosynthesis, and Function of Salivary MucinsAnnual Review of Physiology, 1995
- Recent research into the nature of cerebrospinal fluid formation and absorptionJournal of Neurosurgery, 1983